You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMitomycin
Accession NumberDB00305  (APRD00284)
TypeSmall Molecule
GroupsApproved
DescriptionAn antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional alkylating agents causing cross-linking of DNA and inhibition of DNA synthesis. [PubChem]
Structure
Thumb
Synonyms
7-Amino-9alpha-methoxymitosane
Ametycine
Mitamycin
Mitocin-C
Mitomycin
Mitomycin C
MMC
Mutamycin
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Mitomycin for Injectionpowder for solution5 mgintravenous; intravesicalTeva Canada Limited1997-10-22Not applicableCanada
Mitomycin for Injectionpowder for solution20 mgintravenous; intravesicalTeva Canada Limited1997-10-22Not applicableCanada
Mitomycin for Injection USPpowder for solution5 mgintravenous; intravesicalHospira Healthcare Corporation1998-07-15Not applicableCanada
Mitomycin for Injection USPpowder for solution20 mgintravenous; intravesicalHospira Healthcare Corporation1998-03-12Not applicableCanada
MitosolkitureteralMobius Therapeutics LLC2012-02-08Not applicableUs
Mutamycin Inj 20mg/vialpowder for solution20 mgintravenous; intravesicalBristol Myers Squibb Canada1984-12-312006-05-29Canada
Mutamycin Inj 5mg/vialpowder for solution0.5 mgintravenous; intravesicalBristol Myers Squibb Canada1977-12-312006-05-29Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Mitomycininjection, powder, lyophilized, for solution20 mg/40mLintravenousAccord Healthcare Inc2009-06-10Not applicableUs
Mitomycininjection, powder, lyophilized, for solution20 mg/10mLintravenousAccord Healthcare Inc2013-05-03Not applicableUs
Mitomycininjection, powder, lyophilized, for solution5 mg/10mLintravenousAccord Healthcare Inc2009-06-18Not applicableUs
Mitomycininjection, powder, lyophilized, for solution40 mg/10mLintravenousAccord Healthcare Inc2013-05-03Not applicableUs
Mitomycininjection, powder, lyophilized, for solution40 mg/80mLintravenousAccord Healthcare Inc2011-03-11Not applicableUs
Mitomycininjection, powder, lyophilized, for solution5 mg/10mLintravenousAccord Healthcare Inc2013-05-03Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
MitozytrexNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII50SG953SK6
CAS number50-07-7
WeightAverage: 334.3272
Monoisotopic: 334.127719706
Chemical FormulaC15H18N4O5
InChI KeyInChIKey=NWIBSHFKIJFRCO-WUDYKRTCSA-N
InChI
InChI=1S/C15H18N4O5/c1-5-9(16)12(21)8-6(4-24-14(17)22)15(23-2)13-7(18-13)3-19(15)10(8)11(5)20/h6-7,13,18H,3-4,16H2,1-2H3,(H2,17,22)/t6-,7+,13+,15-/m1/s1
IUPAC Name
[(4S,6S,7R,8S)-11-amino-7-methoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.0²,⁷.0⁴,⁶]trideca-1(9),11-dien-8-yl]methyl carbamate
SMILES
CO[C@]12[[email protected]]3N[[email protected]]3CN1C1=C([[email protected]]2COC(N)=O)C(=O)C(N)=C(C)C1=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as mitomycins. These are polycyclic compounds with a structure based on an aziridine ring linked to a 7-amino-6-methyl-cyclohexa[b]pyrrolizine-5,8-dione.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassIndoles and derivatives
Sub ClassIndolequinones
Direct ParentMitomycins
Alternative Parents
Substituents
  • Mitomycin
  • Indole
  • Quinone
  • Pyrrolizine
  • Piperazine
  • 1,4-diazinane
  • Vinylogous amide
  • Pyrroline
  • Pyrrolidine
  • Tertiary amine
  • Ketone
  • Azacycle
  • Secondary amine
  • Enamine
  • Secondary aliphatic amine
  • Aziridine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor treatment of malignant neoplasm of lip, oral cavity, pharynx, digestive organs, peritoneum, female breast, and urinary bladder. Also used as an adjunct to ab externo glaucoma surgery.
PharmacodynamicsMitomycin is one of the older chemotherapy drugs, which has been around and in use for decades. It is an antibiotic which has been shown to have antitumor activity. Mitomycin selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of mitomycin-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed. Mitomycin has been shown in vitro to inhibit B cell, T cell, and macrophage proliferation and impair antigen presentation, as well as the secretion of interferon gamma, TNFa, and IL-2.
Mechanism of actionMitomycin is activated in vivo to a bifunctional and trifunctional alkylating agent. Binding to DNA leads to cross-linking and inhibition of DNA synthesis and function. Mitomycin is cell cycle phase-nonspecific.
Related Articles
AbsorptionErratic.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Primarily hepatic, some in various other tissues.

Route of eliminationApproximately 10% of a dose of mitomycin is excreted unchanged in the urine.
Half life8-48 min
ClearanceNot Available
ToxicityOral, mouse: LD50 = 23 mg/kg; Oral, rat: LD50 = 30 mg/kg. Symptoms of overdose include nausea and vomiting.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9154
Blood Brain Barrier-0.9659
Caco-2 permeable-0.6572
P-glycoprotein substrateSubstrate0.7861
P-glycoprotein inhibitor INon-inhibitor0.7231
P-glycoprotein inhibitor IINon-inhibitor0.5469
Renal organic cation transporterNon-inhibitor0.8032
CYP450 2C9 substrateNon-substrate0.8997
CYP450 2D6 substrateNon-substrate0.8332
CYP450 3A4 substrateSubstrate0.6879
CYP450 1A2 substrateNon-inhibitor0.5813
CYP450 2C9 inhibitorNon-inhibitor0.7642
CYP450 2D6 inhibitorNon-inhibitor0.7464
CYP450 2C19 inhibitorNon-inhibitor0.6115
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5204
Ames testAMES toxic0.9107
CarcinogenicityNon-carcinogens0.9263
BiodegradationNot ready biodegradable1.0
Rat acute toxicity4.0153 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9788
hERG inhibition (predictor II)Non-inhibitor0.7214
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Accord healthcare inc
  • Baxter healthcare corp anesthesia and critical care
  • Bedford laboratories div ben venue laboratories inc
  • Hospira inc
  • Supergen inc
  • Bristol laboratories inc div bristol myers co
  • Bristol myers co
Packagers
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionintravenous20 mg/40mL
Injection, powder, lyophilized, for solutionintravenous20 mg/10mL
Injection, powder, lyophilized, for solutionintravenous40 mg/80mL
Injection, powder, lyophilized, for solutionintravenous40 mg/10mL
Injection, powder, lyophilized, for solutionintravenous5 mg/10mL
Powder for solutionintravenous; intravesical20 mg
Powder for solutionintravenous; intravesical5 mg
Kitureteral
Powder for solutionintravenous; intravesical0.5 mg
Prices
Unit descriptionCostUnit
Mutamycin 40 mg vial878.48USD vial
Mutamycin 20 mg vial434.8USD vial
Mitomycin 40 mg vial300.0USD vial
Mitomycin 20 mg vial142.55USD vial
Mutamycin 5 mg vial128.75USD vial
Mitomycin 5 mg vial52.43USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7806265 No2009-02-012029-02-01Us
US8186511 No2006-07-192026-07-19Us
US9205075 No2006-07-192026-07-19Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point>360 °CPhysProp
boiling point534 °CPhysProp
water solubilitySoluble (8430 mg/L)Not Available
logP-0.40HANSCH,C ET AL. (1995)
pKa10.9HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility10.1 mg/mLALOGPS
logP-0.55ALOGPS
logP-3ChemAxon
logS-1.5ALOGPS
pKa (Strongest Acidic)-0.3ChemAxon
pKa (Strongest Basic)6.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area146.89 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity83.27 m3·mol-1ChemAxon
Polarizability32.77 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Leslie Jimenez, Zheng Wang, “Synthesis of mitomycin and its analogs.” U.S. Patent US5523411, issued June, 1972.

US5523411
General ReferencesNot Available
External Links
ATC CodesL01DC03
AHFS Codes
  • 10:00.00
PDB EntriesNot Available
FDA labelDownload (82.3 KB)
MSDSDownload (77.9 KB)
Interactions
Drug Interactions
Drug
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Mitomycin.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Mitomycin.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Mitomycin.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Mitomycin.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Mitomycin.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Mitomycin.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Mitomycin.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Mitomycin.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Mitomycin.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Mitomycin.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Mitomycin.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Mitomycin.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Mitomycin.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Mitomycin.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Mitomycin.
BevacizumabBevacizumab may increase the cardiotoxic activities of Mitomycin.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Mitomycin.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Mitomycin.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Mitomycin.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Mitomycin.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Mitomycin.
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mitomycin.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Mitomycin.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Mitomycin.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Mitomycin.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Mitomycin.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Mitomycin.
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Mitomycin.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Mitomycin.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Mitomycin.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Mitomycin.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Mitomycin.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Mitomycin.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Mitomycin.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Mitomycin.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Mitomycin.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Mitomycin.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Mitomycin.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Mitomycin.
ClozapineThe risk or severity of adverse effects can be increased when Mitomycin is combined with Clozapine.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Mitomycin.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Mitomycin.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Mitomycin.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Mitomycin.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Mitomycin.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Mitomycin.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Mitomycin.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Mitomycin.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Mitomycin.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Mitomycin.
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Mitomycin.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Mitomycin.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Mitomycin.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Mitomycin.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Mitomycin.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Mitomycin.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Mitomycin.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Mitomycin.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Mitomycin.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Mitomycin.
DigoxinDigoxin may decrease the cardiotoxic activities of Mitomycin.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Mitomycin.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Mitomycin.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Mitomycin.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Mitomycin.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Mitomycin.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mitomycin.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Mitomycin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Mitomycin.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Mitomycin.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Mitomycin.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Mitomycin.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Mitomycin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Mitomycin.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Mitomycin.
EstriolThe serum concentration of Estriol can be increased when it is combined with Mitomycin.
EstroneThe serum concentration of Estrone can be increased when it is combined with Mitomycin.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Mitomycin.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Mitomycin.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Mitomycin.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Mitomycin.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Mitomycin.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Mitomycin.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Mitomycin.
FingolimodMitomycin may increase the immunosuppressive activities of Fingolimod.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Mitomycin.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Mitomycin.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Mitomycin.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Mitomycin.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Mitomycin.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Mitomycin.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Mitomycin.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Mitomycin.
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Mitomycin.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Mitomycin.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Mitomycin.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Mitomycin.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Mitomycin.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Mitomycin.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Mitomycin.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Mitomycin.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Mitomycin.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Mitomycin.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Mitomycin.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Mitomycin.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Mitomycin.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Mitomycin.
LeflunomideThe risk or severity of adverse effects can be increased when Mitomycin is combined with Leflunomide.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Mitomycin.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Mitomycin.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Mitomycin.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Mitomycin.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Mitomycin.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Mitomycin.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Mitomycin.
LosartanThe serum concentration of Losartan can be increased when it is combined with Mitomycin.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Mitomycin.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Mitomycin.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Mitomycin.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Mitomycin.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Mitomycin.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Mitomycin.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Mitomycin.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Mitomycin.
MorphineThe serum concentration of Morphine can be increased when it is combined with Mitomycin.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Mitomycin.
NadololThe serum concentration of Nadolol can be increased when it is combined with Mitomycin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Mitomycin.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Mitomycin.
NatalizumabThe risk or severity of adverse effects can be increased when Mitomycin is combined with Natalizumab.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Mitomycin.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Mitomycin.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Mitomycin.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Mitomycin.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Mitomycin.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Mitomycin.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Mitomycin.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Mitomycin.
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Mitomycin.
OuabainOuabain may decrease the cardiotoxic activities of Mitomycin.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Mitomycin.
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mitomycin.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Mitomycin.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Mitomycin.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Mitomycin.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Mitomycin.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mitomycin.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Mitomycin.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Mitomycin.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Mitomycin.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Mitomycin.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Mitomycin.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Mitomycin.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Mitomycin.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Mitomycin.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Mitomycin.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Mitomycin.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Mitomycin.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Mitomycin.
QuinineThe serum concentration of Quinine can be increased when it is combined with Mitomycin.
Rabies vaccineThe risk or severity of adverse effects can be increased when Mitomycin is combined with Rabies vaccine.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Mitomycin.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Mitomycin.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Mitomycin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Mitomycin.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Mitomycin.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Mitomycin.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Mitomycin.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Mitomycin.
RoflumilastRoflumilast may increase the immunosuppressive activities of Mitomycin.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Mitomycin.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Mitomycin.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Mitomycin.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Mitomycin.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Mitomycin.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Mitomycin.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Mitomycin.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Mitomycin.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Mitomycin.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Mitomycin.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Mitomycin.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Mitomycin.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Mitomycin.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Mitomycin.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Mitomycin.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Mitomycin.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Mitomycin.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Mitomycin.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Mitomycin.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Mitomycin.
TimololThe serum concentration of Timolol can be increased when it is combined with Mitomycin.
TofacitinibMitomycin may increase the immunosuppressive activities of Tofacitinib.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Mitomycin.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Mitomycin.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Mitomycin.
TrastuzumabTrastuzumab may increase the neutropenic activities of Mitomycin.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Mitomycin.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Mitomycin.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Mitomycin.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Mitomycin.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Mitomycin.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Mitomycin.
VinblastineThe risk or severity of adverse effects can be increased when Vinblastine is combined with Mitomycin.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Mitomycin.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Mitomycin.
VincristineThe risk or severity of adverse effects can be increased when Vincristine is combined with Mitomycin.
VindesineThe risk or severity of adverse effects can be increased when Vindesine is combined with Mitomycin.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Mitomycin.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Mitomycin.
Food InteractionsNot Available

Targets

1. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
yes
Actions
antagonistcross-linking/alkylation
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Rodighiero G, Marciani Magno S, Dell'Acqua F, Vedaldi D: Studies on the mechanism of action of mitomycin C. Farmaco Sci. 1978 Sep;33(9):651-66. [PubMed:744262 ]
  4. Verweij J, Pinedo HM: Mitomycin C: mechanism of action, usefulness and limitations. Anticancer Drugs. 1990 Oct;1(1):5-13. [PubMed:2131038 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, nad(p)h as one donor, and incorporation of one atom of oxygen
Specific Function:
This enzyme is required for electron transfer from NADP to cytochrome P450 in microsomes. It can also provide electron transfer to heme oxygenase and cytochrome B5.
Gene Name:
POR
Uniprot ID:
P16435
Molecular Weight:
76689.12 Da
References
  1. Bligh HF, Bartoszek A, Robson CN, Hickson ID, Kasper CB, Beggs JD, Wolf CR: Activation of mitomycin C by NADPH:cytochrome P-450 reductase. Cancer Res. 1990 Dec 15;50(24):7789-92. [PubMed:2123741 ]
  2. Vromans RM, van de Straat R, Groeneveld M, Vermeulen NP: One-electron reduction of mitomycin c by rat liver: role of cytochrome P-450 and NADPH-cytochrome P-450 reductase. Xenobiotica. 1990 Sep;20(9):967-78. [PubMed:2122607 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 29, 2016 02:27